Clinical Trial Update: Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating infliximab plus intravenous immunoglobulin as initial treatment for Kawasaki disease has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kawasaki Disease

Drugs mentioned

• Intravenous Immunoglobulin (IVIG)
• Remicade (infliximab)

Snippet

Sponsor: University of California, San Diego | Conditions: Kawasaki Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-11-13